MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia

Rui Wang, PhD,* Anna Laveskog, MD,* Erika J. Laukka, PhD, Grégoria Kalpouzos, PhD, Lars Bäckman, PhD, Laura Fratiglioni, MD, PhD, and Chengxuan Qiu, PhD

Neurology® 2018;91:e1487-e1497. doi:10.1212/WNL.0000000000006355

Abstract

Objective
To explore the differential associations of neurodegeneration and microvascular lesion load with cognitive decline and dementia in older people and the modifying effect of the APOE genotype on these associations.

Methods
A sample of 436 participants (age ≥ 60 years) was derived from the population-based Swedish National study on Aging and Care in Kungsholmen, Stockholm, and clinically examined at baseline (2001–2003) and 3 occasions during the 9-year follow-up. At baseline, we assessed microvascular lesion load using a summary score for MRI markers of lacunes, white matter hyperintensities (WMHs), and perivascular spaces and neurodegeneration load for markers of enlarged ventricles, smaller hippocampus, and smaller gray matter. We assessed cognitive function using the Mini-Mental State Examination (MMSE) test and diagnosed dementia following the Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria. We analyzed data using linear mixed-effects, mediation, and random-effects Cox models.

Results
During the follow-up, 46 participants were diagnosed with dementia. Per 1-point increase in microvascular lesion and neurodegeneration score (range 0–3) was associated with multiple adjusted β-coefficients of −0.35 (95% confidence interval, −0.51 to −0.20) and −0.44 (−0.56 to −0.32), respectively, for the MMSE score and multiple adjusted hazard ratios of 1.68 (1.12–2.51) and 2.35 (1.58–3.52), respectively, for dementia; carrying APOE ε4 reinforced the associations with MMSE decline. WMH volume changes during the follow-up mediated 66.9% and 12.7% of the total association of MMSE decline with the baseline microvascular score and neurodegeneration score, respectively.

Conclusions
Both cerebral microvascular lesion and neurodegeneration loads are strongly associated with cognitive decline and dementia. The cognitive decline due to microvascular lesions is exacerbated by APOE ε4 and is largely attributed to progression and development of microvascular lesions.

*These authors contributed equally to this work.

From the Department of Neurobiology (R.W., E.J.L., G.K., L.B., C.Q.), Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University; Division of Radiology (A.L.), Department of Clinical Science, Intervention and Technology, Karolinska University Hospital at Huddinge; Department of Neuroradiology (A.L.), Karolinska University Hospital, Stockholm; and Stockholm Gerontology Research Center (L.F.), Stockholm, Sweden.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by Swedish Research Council.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cerebral small vessel disease (SVD) is visualized on MRI as white matter hyperintensities (WMHs), lacunes, perivascular spaces (PVSs), microbleeds, and brain atrophy. Studies have shown that SVD plays a pivotal role in cognitive decline and dementia, but most studies have examined individual markers. Because SVD markers often occur concurrently in older people, a cluster of SVD markers may better capture the extent and severity of microvascular and neurodegenerative damage than single markers and better reflect their cognitive phenotypes. Cross-sectional studies have suggested a strong correlation of heavy SVD load with cognitive deficits, whereas longitudinal data are still lacking.

Furthermore, neuropathologic studies have correlated MRI markers of regional and global brain atrophy (e.g., hippocampal atrophy and enlarged ventricles) with neurodegenerative pathologies. Notably, neurodegenerative and microvascular pathologies share common mechanisms (e.g., inflammation and oxidative stress) and have a reciprocal relationship. For instance, cerebral arteriosclerosis and hypoxia impair perivascular drainage of amyloid and increase neurodegeneration, whereas Alzheimer-related pathologies cause auxiliary vascular damage. Thus, SVD or atrophic markers are likely to reflect a mixture of microvascular and neurodegenerative pathology in the brain.

Therefore, several issues on SVD load and cognitive phenotypes remain to be clarified: (1) whether various SVD markers, which represent different dominant pathologies such as intrinsic arteriolar disease (lacunes and WMH) and neurodegeneration (hippocampal atrophy), have differential effects on cognition is unclear; (2) the extent to which the association of SVD load with cognitive phenotypes is attributed to subsequent structural brain changes is unknown; and (3) whether APOE ε4 interacts with SVD load to affect cognitive decline and dementia has yet to be determined. In this population-based cohort study, we seek to assess the differential associations of microvascular lesion and neurodegeneration load with cognitive decline and dementia and to examine the effect of APOE ε4 on these relationships.

**Methods**

**Study participants**

Participants in this population-based cohort study were derived from the Swedish National study on Aging and Care in Kungsholmen (SNAC-K), a multidisciplinary study of aging and health, Briefly, the SNAC-K participants consisted of an age-stratified random sample of people who were aged 60 years or older and living either at home or in institutions in the Kungsholmen district of central Stockholm, Sweden. The sample included 3 younger age cohorts, each with a 6-year interval (60, 66, and 72 years), that were followed up with every 6 years, and 8 older age cohorts, each with a 3-year interval (78, 81, 84, 87, 90, 93, 96, and 99 + years), that were longitudinally assessed every 3 years. At baseline (March 2001 to August 2004), 3,363 of the 4,590 eligible participants (73.3%) were examined. Participants of the SNAC-K MRI study represented a subsample (n = 555) of the SNAC-K participants who were noninstitutionalized and free of disability and dementia and were recruited between September 2001 and October 2003. In this study, we used 9-year follow-up data for the SNAC-K MRI sample (2001–2003 through 2010–2013). Of the 555 participants, 57 were excluded because of incomplete MRI data or suboptimal image quality (n = 56) or missing data on the Mini-Mental State Examination (MMSE) test at baseline (n = 1). Of the remaining 498 participants, the 431 participants who had at least 1 cognitive assessment at follow-up were included in the analysis concerning cognitive decline, and the 436 participants who had a diagnostic assessment for dementia at follow-up were included in the analysis involving dementia. In addition, 321 of the 498 participants (64.5%) had at least 1 follow-up MRI scan. Figure 1 shows the flowchart of the study participants. Compared with participants who did not undergo brain MRI, the SNAC-K MRI participants were younger and more educated, and the 2 groups did not differ in sex and APOE ε4 allele distribution, as previously reported.

**Standard protocol approvals, registrations, and patient consents**

The Ethics Committee at the Karolinska Institutet or the Regional Ethics Review Board in Stockholm, Sweden, approved all parts of the SNAC-K study, including linkage with patient register and death certificates. All participants provided written informed consent.

**MRI acquisition and reading protocol**

At baseline, participants were scanned on a Philips Intera 1.5T MRI system (Eindhoven, The Netherlands). The core MRI protocol included an axial 3D T1-weighted fast-field-echo sequence (time of repetition [TR] 15 ms, time to echo [TE] 7 ms, flip angle [FA] 15°, field of view [FOV] 20, matrix 256 × 256), a fluid-attenuated inversion recovery [FLAIR] sequence (TR 6,000 ms, TE 100 ms, inversion time 1,900 ms, FA 90°, echo train length 21, FOV 184 × 230, matrix 204 × 256), and a proton density/T2-weighted fast spin-echo sequence (time of repetition [TR] 3,000 ms, echo time [TE] 90 ms, flip angle [FA] 90°, field of view [FOV] 256 × 256). All participants received an intravenous injection of a gadolinium-based contrast agent (gadobenate dimeglumine).
sequence (TR 4,000 ms, TE 18/90 ms, FA 90°, echo train length 6, FOV 187.5 × 250, matrix 192 × 256, 5 mm slices, without the use of gap and angulation). A single rater (G.K.) manually drew global WMH volume on FLAIR images and further interpolated on the corresponding T1 images to compensate for the gap between slices in FLAIR (Dice coefficients ranged 0.74–0.78, and the mean Dice coefficient was 0.76), as previously reported. We segmented T1 images into gray matter, white matter, and CSF using SPM12 in MATLAB R2012b. A specialist in neuroimaging analysis (G.K.) visually inspected all segments. Hippocampal volume in both hemispheres was manually delineated using the region of interest tool, and the lateral ventricular volumes were estimated using a region-growing-based semiautomatic tool in HERMES MultiModality. We also used automated FreeSurfer segmentation to measure hippocampal volume at baseline. The manually and automatically measured hippocampal volumes were highly correlated (r = 0.862, p < 0.001). In this study, we used the manual measurement of hippocampal volume, as we used in previous studies.

We defined lacunes as small lesions with CSF signal on all sequences and surrounding high signals on FLAIR sequence. We used a visual rating scale to evaluate PVS, as fully reported elsewhere. Briefly, we used T1 and T2 images to assess PVS in different brain areas (e.g., frontal lobe, parieto-occipital lobe, basal ganglia, thalamus, and cerebellum) in each brain hemisphere. In each region, the number of visible PVS was measured on a 0–3 point scale: 0, no visible PVS; 1, 1–5 PVS; 2, 6–10 PVS; or 3, >10 PVS. Then, we summed up the point from all brain regions to obtain a global PVS score. A clinical neuroradiologist (A.L.) made all the assessments of PVS. The visual rating scale for PVS had the weighted κ statistic of 0.77 for both intrarater and inter-rater reliability.
Load of MRI markers for microvascular lesions and neurodegeneration

We assessed the cerebral microvascular lesion load and neurodegeneration load separately with 2 MRI scores: (1) the microvascular lesion score summarized the MRI markers of lacunes, WMH, and PVSs because these MRI markers are assumed to reflect predominantly microvascular damage in the brain, and (2) the neurodegeneration score counted the MRI markers of enlarged ventricles, smaller hippocampus, and smaller total gray matter because these MRI markers are usually indicative of Alzheimer-related pathology or neurodegeneration. We calculated each of the 2 MRI scores by summing up the total points of the corresponding MRI markers that were concurrently present in a participant. We assigned 1 point to each of the 6 MRI markers as follows: (1) presence of lacunes, being in the fourth quartile of (2) WMH volume, (3) global PVS score, and (4) lateral ventricular volume, and being in the first quartile of (5) hippocampal volume, and (6) total gray matter volume. Both the microvascular lesion score and neurodegeneration score ranged 0–3.

Global cognitive function and dementia

We used the MMSE test to assess global cognitive function at baseline (2001–2003) for all participants; at 3-year (2004–2007), 6-year (2007–2010), and 9-year (2010–2013) follow-ups for participants aged ≥78 years; at 6-year and 9-year follow-ups for participants aged 72 years; and at 6-year follow-up for participants aged 60 and 66 years.

We used the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, criteria to define dementia according to a validated 3-step diagnostic procedure. Briefly, the examining physician made a first preliminary diagnosis of dementia based on interviews, clinical examination, and cognitive testing; then, a reviewing physician independently made a second preliminary diagnosis; in case of disagreement between the 2 preliminary diagnoses, a third opinion from a senior physician was sought to make the final diagnosis. We defined Alzheimer disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria. For participants who had died before the subsequent follow-up examination, physicians thoroughly reviewed medical records and death certificates to determine whether the participant died with dementia or Alzheimer disease.

Covariates

We collected data on potential confounding factors (as covariates in the analysis) through face-to-face interviews, clinical examinations, and laboratory tests. The confounding factors included demographics (e.g., age, sex, and education), lifestyles (e.g., smoking, alcohol consumption, and physical activity), medical history (e.g., hypertension, diabetes, heart disease, and stroke), use of medications (e.g., antihypertensive agents, oral hypoglycemic agents, and cholesterol-lowering drugs), weight, height, blood pressure, and biomarkers (e.g., total cholesterol, HbA1c, and APOE genotype). Education was measured by the maximum years of formal schooling. We classified all medications according to the Anatomical Therapeutic Chemical (ATC) classification system. Body mass index (BMI) was calculated as measured weight (kg) divided by height (m) squared, and obesity was defined as a BMI ≥30 kg/m². We dichotomized smoking status as never/former vs current smoking, alcohol consumption as heavy vs no or moderate alcohol intake, and physical activity as inactivity vs fitness-enhancing activity. We defined hypertension as arterial blood pressure ≥140/90 mm Hg or current use of antihypertensive drugs (ATC codes C02, C03, and C07-C09); diabetes as having a self-reported history of diabetes, use of oral hypoglycemic agents or insulin (ATC code A10), records of diabetes in patient register, or HbA1c ≥ 6.5%; and high total cholesterol as total cholesterol >6.22 mmol/L or current use of cholesterol-lowering drugs (ATC code C10).

Statistical analysis

We compared the baseline characteristics of participants by APOE ε4 status using logistic regression models, adjusting for age. We used multiple linear mixed-effects models to estimate the β-coefficient and 95% confidence interval (CI) of average annual changes in the MMSE score over the follow-up period related to baseline MRI scores for cerebral microvascular lesions and neurodegeneration. The models included the baseline MRI score, follow-up time, and their interaction term. Because we were interested in the effects of brain MRI load on MMSE changes during follow-up, we reported only β-coefficient (95% CI) for the MRI score × follow-up time interaction term, which reflects additional effect of the MRI score on annual MMSE changes. We used random-effects Cox proportional hazards models to assess the association of MRI scores at baseline with incident dementia, with follow-up time as the time scale. We verified the proportional hazards assumption by plotting log-log survival curves and the Schoenfeld residual test. We tested interactions between an MRI score and APOE ε4 allele by adding the 3-way product term of the MRI score × follow-up time × APOE ε4 allele to the model. When a statistical interaction was detected, we further performed stratifying analysis to verify the direction and magnitude of the interaction. We reported the results from 4 models: model 1 was controlled for age, sex, education, cardiovascular risk factors (e.g., smoking, diabetes, and hypertension), and APOE ε4 allele; in model 2, we simultaneously entered the baseline MRI scores for both cerebral microvascular lesions and neurodegeneration into model 1 to assess their independent effects on cognitive outcomes; to assess the effect of structural brain changes that occurred during the follow-ups on the association of baseline MRI scores with cognitive decline and dementia, in model 3, we added follow-up WMH volume (a marker of microvascular lesions) to model 1; and in model 4, we added follow-up total gray matter volume (a marker of neurodegeneration).
to model 3. Finally, for the analysis involving cognitive decline, we also performed mediation analysis to test and quantify the mediation effect of structural brain changes occurred during the follow-up on the association between baseline MRI score and MMSE decline, in which we used bootstrapping methods to estimate the 95% CI. We used Stata 14.0 for Windows (StataCorp LP, College Station, TX) for all analyses.

**Data availability**

Data related to the current study are derived from the SNAC-K and SNAC-K/MRI projects (snac-k.se). Access to these anonymized SNAC-K and SNAC-K/MRI data will be available from the corresponding author (C.Q.) upon reasonable request and approval by the SNAC-K data management and maintenance committee at the Aging Research Center, Karolinska Institutet, Stockholm, Sweden.

**Results**

At baseline, the mean age of the 436 participants was 70.3 years (SD = 9.1), and 61.0% were women. After controlling for age, carriers and noncarriers of the APOE ε4 allele did not significantly differ for all baseline characteristics examined, except the total cholesterol level where the APOE ε4 allele carriers had higher total cholesterol than the noncarriers (table 1). In addition, the age- and sex-adjusted partial correlation coefficient between the baseline microvascular lesion score and neurodegeneration score was 0.05 (p = 0.30).

During the 9-year follow-up period, the average annual rate of MMSE changes was −0.63 (95% CI, −0.75 to −0.51; p < 0.001), after controlling for age, sex, and education. A higher MRI score for both microvascular lesions and neurodegeneration at baseline was associated with faster MMSE.

### Table 1 Baseline characteristics of study participants (n = 436) by APOE ε4 allele status

| Characteristics                   | Total sample (n = 436) | APOE ε4 allele<br>a Yes (n = 115) | p Value<br>d |
|-----------------------------------|------------------------|----------------------------------|--------------|
| Age (y), mean (SD)                | 70.3 (9.1)             | 69.6 (8.6)                       | 0.365        |
| Female, n (%)                     | 266 (61.0)             | 73 (63.5)                        | 0.590        |
| Education, n (%)                  |                        |                                  |              |
| Elementary school                 | 51 (11.7)              | 12 (10.4)                        |              |
| Middle school                     | 197 (45.2)             | 52 (45.2)                        |              |
| University                        | 188 (43.1)             | 51 (44.4)                        | 0.694        |
| Hypertension, n (%)               | 313 (71.8)             | 78 (67.8)                        | 0.374        |
| Diabetes mellitus, n (%)          | 28 (6.4)               | 4 (3.5)                          | 0.167        |
| BMI (kg/m²), mean (SD)b           | 26.0 (4.1)             | 25.8 (3.4)                       | 0.448        |
| Total cholesterol (mmol/L), mean (SD)b | 6.2 (1.1)              | 6.4 (0.9)                        | 0.048        |
| Current smoking, n (%)            | 50 (11.5)              | 11 (9.6)                         | 0.391        |
| Heavy alcohol drinking, n (%)     | 79 (18.1)              | 21 (18.3)                        | 0.970        |
| Physical inactivity, n (%)        | 83 (19.0)              | 16 (13.9)                        | 0.120        |
| MMSE score, mean (SD)             | 29.1 (1.1)             | 29.0 (1.1)                       | 0.495        |
| Lacunar infarcts, n (%)           | 51 (11.7)              | 9 (7.8)                          | 0.174        |
| PVS score, median (IQR)           | 30 (24–34)             | 30 (23–33)                       | 0.554        |
| WMH volume, mean (SD)c            | 0.42 (0.74)            | 0.48 (0.76)                      | 0.161        |
| Total gray matter volume, mean (SD)c | 36.97 (3.62)          | 37.28 (3.58)                     | 0.529        |
| Hippocampal volume, mean (SD)c    | 0.45 (0.06)            | 0.45 (0.06)                      | 0.178        |
| Ventricular volume, mean (SD)c    | 1.82 (1.08)            | 1.80 (1.08)                      | 0.796        |

Abbreviations: BMI = body mass index; IQR = interquartile range; MMSE = Mini-Mental State Examination; PVS = perivascular space; WMH = white matter hyperintensities.

a Information on the APOE genotype was missing in 6 participants.

b The numbers of participants with missing value were 1 for BMI and 6 for total cholesterol. The missing values were replaced with their mean in further analyses.

c Volume was corrected for total intracranial volume, and data are mean (SD) of percentage of the volume over the total intracranial volume.

d p Value was adjusted for age.
decline, independent of demographics, cardiovascular risk factors, and APOE e4 status (p for trend < 0.01) (table 2, model 1). Furthermore, when simultaneously entering baseline MRI scores into the model, the linear association (β-coefficient) with MMSE decline remained statistically significant for both MRI scores, although the association with the neurodegeneration score appeared to be stronger than that for the microvascular lesion score (table 2, model 2).

Of the 498 baseline participants, 321 (64.5%) undertook at least 1 follow-up MRI scan, and data on follow-up WMH and total gray matter volumes were available. During the follow-up period, WMH volume increased at the average rate of 1.45 mL per year (95% CI, 1.14–1.76; p < 0.001) (standardized β-coefficient 0.17), whereas the total gray matter volume decreased at the average rate of 11.03 mL per year (95% CI, −12.03 to −10.03; p < 0.001) (standardized β-coefficient −0.15). When entering follow-up WMH volume variable into the model, the associations of both MRI scores at baseline with MMSE decline remained statistically significant (table 2, model 3); notably, the linear relationship with MMSE decline remained statistically significant for the neurodegeneration score (p for linear trend <0.01) but not for the microvascular lesion score. Further entering follow-up total gray matter volume variable into model 3 had almost no effect on the results (table 2, model 4).

In the mediation analysis, after controlling for a range of potential confounders, 66.9% of the total association of MMSE decline with the baseline microvascular lesion score, but only 12.7% of the total association with the baseline neurodegeneration score, was attributed to WMH changes that occurred over the follow-up period. In contrast, changes in total gray matter volume that occurred during the follow-up period could explain only 12.8% and 2.2% of the total associations of MMSE decline with the baseline microvascular lesion score and neurodegeneration score, respectively (figure 2).

There was a reliable interaction of APOE e4 status with scores for both microvascular lesions and neurodegeneration on MMSE decline (p for interaction <0.01). A stratifying analysis revealed a linear association between microvascular lesions and MMSE decline only among APOE e4 allele carriers (figure 3). In addition, carrying the APOE e4 allele magnified

Table 2  Associations of baseline MRI scores for microvascular lesions and neurodegeneration with annual changes in the MMSE score

| Baseline MRI scores for microvascular lesions and neurodegeneration | No. of participants | β-coefficient (95% confidence interval), average annual changes in the MMSE score |
|---------------------------------------------------------------|-------------------|--------------------------------------------------------------------------|
| Microvascular lesion score                                    |                   | β-coefficient (95% confidence interval), average annual changes in the MMSE score |
| Continuous (range 0–3)                                        | 431               | Model 1*         | Model 2b        | Model 3c        | Model 4d        |
| Continuous (range 0–3)                                        | 431               | −0.35 (−0.51 to −0.20)       | −0.20 (−0.36 to −0.05)       | −0.03 (−0.16 to 0.09)       | −0.02 (−0.15 to 0.11)       |
| Categorical                                                   |                   | 0 (reference)            | 0 (reference)            | 0 (reference)            | 0 (reference)            |
| 0                                                             | 245               | −0.42 (−0.68 to −0.16)       | −0.21 (−0.47 to 0.05)       | −0.19 (−0.39 to 0.02)       | −0.17 (−0.37 to 0.03)       |
| 1                                                             | 131               | −0.67 (−1.04 to −0.31)       | −0.38 (−0.74 to −0.01)       | 0.02 (−0.28 to 0.32)       | 0.05 (−0.25 to 0.35)       |
| ≥2                                                            | 55                |                              |                              |                              |                              |
| p Value for trend*                                             | <0.001            | 0.023                      | 0.477                      | 0.620                      |
| Neurodegeneration score                                        |                   | β-coefficient (95% confidence interval), average annual changes in the MMSE score |
| Continuous (range 0–3)                                        | 431               | Model 1*         | Model 2b        | Model 3c        | Model 4d        |
| Continuous (range 0–3)                                        | 431               | −0.44 (−0.56 to −0.32)       | −0.39 (−0.51 to −0.27)       | −0.22 (−0.32 to −0.11)       | −0.21 (−0.32 to −0.11)       |
| Categorical                                                   |                   | 0 (reference)            | 0 (reference)            | 0 (reference)            | 0 (reference)            |
| 0                                                             | 235               | −0.49 (−0.76 to −0.23)       | −0.46 (−0.73 to −0.19)       | −0.44 (−0.64 to −0.23)       | −0.44 (−0.64 to −0.23)       |
| 1                                                             | 104               | −1.05 (−1.34 to −0.76)       | −0.93 (−1.24 to −0.63)       | −0.40 (−0.65 to −0.15)       | −0.39 (−0.64 to −0.14)       |
| ≥2                                                            | 92                |                              |                              |                              |                              |
| p Value for trend*                                             | <0.001            | <0.001                    | <0.001                    | <0.001                    |

Abbreviation: MMSE = Mini-Mental State Examination.
* Model 1, adjusted for demographic factors, cardiovascular risk factors (i.e., hypertension, obesity, physical inactivity, high cholesterol, current smoking, heavy drinking, and diabetes), and APOE e4 allele.
* Model 2, the 2 baseline MRI scores for cerebral microvascular lesions and neurodegeneration were added simultaneously to model 1.
* Model 3, follow-up white matter hyperintensity volume was added to model 1.
* Model 4, follow-up total gray matter volume was added to model 3.
* p Value is for the test of a linear trend for association between the baseline MRI score and the β-coefficient of average annual changes in the MMSE score that was derived from the model when the score was entered as a continuous variable (coded as 0, 1, and 2 if the score ≥2).
* p < 0.05.
* p < 0.01.
the association between the neurodegeneration load and MMSE decline.

During the 9-year follow-up period, 46 participants were diagnosed with dementia; of these, 27 were classified to have Alzheimer disease. Increased MRI scores for microvascular lesions and neurodegeneration were linked to an increased risk of dementia (table 3, model 1); when simultaneously entering the 2 MRI scores into the model, the linear trend of an association with the risk of dementia was statistically significant only for the neurodegeneration score (table 3, model 2). Further adding the variables of follow-up WMH and total gray matter volumes to the model did not substantially alter the association between either score at baseline and risk of incident dementia (table 3, models 3 and 4). There was no significant interaction between the baseline MRI scores and APOE ε4 allele on the risk of dementia. The results for the associations between the baseline MRI scores and risk of Alzheimer disease were similar to those for dementia in general (table e-1, links.lww.com/WNL/A702).

Finally, we repeated the analyses only among participants who undertook at least 1 follow-up brain MRI scan and who had data available on global WMH and total gray matter volumes (n = 321), which yielded results that were consistent with those reported in tables 2 and 3 (data not shown).

**Discussion**

This population-based cohort study of older adults revealed that (1) an increasing load for both cerebral microvascular lesions and neurodegeneration is strongly associated with a faster decline of global cognitive function and a greater risk of dementia and Alzheimer disease, and neurodegeneration load appears to have a stronger and more prominent association with cognitive decline and dementia risk than that of microvascular lesion load; (2) the association of microvascular lesion load with subsequent cognitive decline is largely (~67%) attributed to the progression and development of WMH; and (3) carrying APOE ε4 allele strengthens the
association of brain MRI load with cognitive decline, especially with regard to the cerebral microvascular lesion load.

A correlation of cerebral SVD load with global cognitive impairment and dementia has been reported in cross-sectional studies of community-dwelling older people.6,7 In the current cohort study, we categorized all 6 MRI markers of brain lesions into microvascular lesions and neurodegeneration and revealed a more prominent association of neurodegeneration load with cognitive decline and risk of dementia than that of microvascular lesion load. The classification of MRI markers is based on the facts that lacunes and WMH are considered to be of vascular origin because of cerebral arteriosclerosis and hypoperfusion,19,20 and enlarged PVS can signal microvascular lesions,23 whereas postmortem MRI studies correlated hippocampal atrophy with local increased burden of Alzheimer pathologies (e.g., β amyloid and tau protein) and sclerosis,9,24 and ventricular enlargement was a summary marker of global gray and white matter atrophy.8,25 However, cerebral microvascular and neurodegenerative pathologies share both risk factors (e.g., smoking, hypertension, and APOE gene) and biological mechanisms (e.g., inflammation and oxidative stress),26,27 and neurodegenerative pathologies in aging may cause cerebral perfusion deficits that precede volume loss.28 Also, cerebral microvascular and neurodegenerative pathologies often coexist in older people,8,29 and neuropathologic studies have linked volumetric brain measurements (e.g., enlarged ventricles and gray matter atrophy) with mixed Alzheimer and cerebrovascular pathologies (e.g., neuritic plaques, neurofibrillary tangles, arteriosclerosis, and infarcts).8,20 Thus, we should be aware that MRI markers for cerebral microvascular lesions and neurodegeneration do not necessarily represent distinct brain pathologies. Toward this end, our findings are in line with the view that the total burden

**Figure 3** Association of the baseline MRI scores for cerebral microvascular lesions (A) and neurodegeneration (B) with average annual changes in MMSE score by APOE ε4 status

| A. Microvascular lesions | B. Neurodegeneration |
|-------------------------|----------------------|
| **APOE ε4 noncarriers** | **APOE ε4 carriers** |
| n = 173                 | n = 71               |
| n = 99                  | n = 28               |
| n = 40                  | n = 14               |
| Ref.                   | Ref.                 |
| β-coefficient (95% CI) | MMSE score           |
| 0                       | 0                    |
| 1                       | 1                    |
| ≥2                      | ≥2                   |

MMSE = Mini-Mental State Examination; WMH = white-matter hyperintensities. Model 1, adjusted for demographic factors and cardiovascular risk factors; model 2, the 2 baseline MRI scores for microvascular lesions and neurodegeneration were added simultaneously to model 1. *p < 0.05; **p < 0.01.
of cerebral mixed vascular and neurodegenerative alterations is the strongest determinant of cognitive phenotypes in aging. The interactive effect of SVD load with APOE e4 allele on cognitive decline is consistent with findings of interactions between APOE e4 allele and individual markers for microvascular (e.g., WMH) and neurodegenerative (e.g., neuritic plaques and neurofibrillary tangles) lesions on cognitive phenotypes in aging. Both cerebral microvascular lesion and neurodegeneration loads had a strong association with subsequent cognitive decline and dementia risk in older adults. Because MRI markers for neurodegeneration are more likely to reflect mixed microvascular and neurodegenerative pathologies, the apparent stronger effect of neurodegeneration load than that of microvascular lesions on global cognitive decline and the risk of dementia suggests that clusters of various brain MRI markers with different underlying neuropathologies may act interactively to contribute to substantial cognitive decline and dementia risk. This is consistent with the clinical data showing that markers of neurodegeneration are more prominent determinants of global cognitive deficits than those of microvascular lesions (e.g., WMH, microbleeds, and lacunes). A cohort study of middle-aged people with a family history of Alzheimer disease also demonstrated that clusters of MRI and CSF markers for various types of brain pathology were differentially related to patterns of cognitive decline.

Because nearly two-thirds of participants had follow-up MRI data in our study, we were able to explore the effect of structural brain changes on the association of baseline cerebral SVD load with cognitive decline and dementia. Our mediation analysis suggested that the association of microvascular lesion load with subsequent cognitive decline was largely mediated by follow-up changes in WMH volume, whereas the association of neurodegeneration load to cognitive decline was independent of changes in volumes of both WMH and total gray matter during the follow-up. This implies that the association between cerebral microvascular lesions and subsequent cognitive decline is attributed to the progression or new development of cerebral microvascular lesions, suggesting a vascular nature of the cognitive decline. This is a critical finding, as it may imply that interventions aiming to slow the progression and development of microvascular lesions (e.g., WMH) might attenuate cognitive decline in aging. However,
we found little evidence that structural brain changes (WMH and total gray matter) influenced the link of brain MRI load to subsequent risk of dementia.

Major strengths of our study include the population-based design, longitudinal assessment of structural brain integrity, and comprehensive control of potential confounders. Our study also has limitations. First, the study sample had higher socioeconomic positions than the average Swedish population and was younger and healthier than the target population. Thus, one should be cautious in generalizing our findings to other populations. Furthermore, the MMSE test may not be sensitive to subtle cognitive changes and may be subject to practice effects when administered in a series of assessments. Third, MRI sequences for additional MRI markers for brain lesions such as cerebral microbleeds and microinfarcts were not available, which might have underestimated the effect of cerebral microvascular lesion load on cognitive outcomes. Finally, some MRI markers that we used for neurodegeneration (e.g., enlarged ventricle) may correlate also with brain vascular pathology, which needs to be kept in mind when interpreting our findings.

Overall, our population-based cohort study demonstrates a strong association of MRI load for both microvascular lesions and neurodegeneration with global cognitive decline and risk of dementia in older people. The cognitive consequences of cerebral microvascular lesion load largely stem from its progression or development of new cerebral microvascular lesions. This suggests that a structural MRI-based score approach for brain lesions may help identify individuals at risk for accelerated cognitive decline and dementia, for clinical trials, as well as for preventive interventions targeting vascular pathways that aim to delay the onset of late-life cognitive impairment and dementia.

Author contributions
Study concept and design: R. Wang, A. Laveskog, E.J. Laukka, L. Bäckman, L. Fratiglioni, and C. Qiu. Data acquisition: A. Laveskog, G. Kalpouzos, E.J. Laukka, and L. Fratiglioni. Data analysis: R. Wang. Interpretation of data: all authors. Drafting of the manuscript: R. Wang and C. Qiu. Critical revision of the manuscript: all authors. R. Wang had full access to all data in this study and takes responsibility for the integrity of data and the accuracy of data analysis.

Acknowledgment
The authors thank all the SNAC-K participants and their colleagues in the SNAC-K Study Group for their collaboration in data collection and management.

Study funding
SNAC-K is supported by the Swedish Ministry of Health and Social Affairs, the participating County Councils and Municipalities, and the Swedish Research Council. This work was further supported by grants from the Swedish Research Council (grants nos. 2015-02531, 2016-06658, and 2017-05819), the Swedish Research Council for Health, Working Life and Welfare (grant no. 2014-01382), the Karolinska Institutet, Stockholm, Sweden, and the European Union Horizon 2020 Framework Programme for Research and Innovation (grant no. 667375). L. Bäckman was supported by an Alexander von Humboldt Research Award and a donation from the af Jochnick Foundation. The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.

Disclosure
R. Wang was supported by a grant from the Swedish Research Council (grant no. 2016-06658). A. Laveskog, E. Laukka, and G. Kalpouzos report no disclosures relevant to the manuscript. L. Bäckman was supported by an Alexander von Humboldt Research Award and a donation from the af Jochnick Foundation. L. Fratiglioni was supported by the European Union Horizon 2020 Framework Programme for Research and Innovation (grant no. 667375). C. Qiu was supported by grants from the Swedish Research Council (grants nos. 2015-02531 and 2017-05819), the Swedish Research Council for Health, Working Life and Welfare (grant no. 2014-01382), and the Karolinska Institutet, Stockholm, Sweden. Go to Neurology.org/N for full disclosures.

Publication history
Received by Neurology January 5, 2018. Accepted in final form July 12, 2018.

References
1. Wardlaw JM, Smith EE, Biberes GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–838.
2. Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol 2015;12:267–277.
3. Ding J, Sigurdsson S, Jönsson PV, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology 2017;88:2089–2097.
4. Ding J, Sigurdsson S, Jönsson PV, et al. Large perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the age, gene/environment susceptibility-reykjavik study. JAMA Neurol 2017;74:1105–1112.
5. Lopez OL, Klunk WE, Mathis C, et al. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 2014;83:1804–1811.
6. Staals J, Booth T, Morris Z, et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people. Neurobiol Aging 2015;36:2806–2811.
7. Xu X, Hild S, Collinson SL, et al. Validation of the total cerebrovascular disease burden scale in a community sample. J Alzheimers Dis 2016;52:1021–1028.
8. Ertun-Lyons D, Dodge HH, Woltjer R, et al. Neuropathologic basis of age-associated brain atrophy. JAMA Neurol 2013;70:616–622.
9. Kotrotsou A, Schneider JA, Bennett DA, et al. Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiol Aging 2015;36:2798–2805.
10. Brehmer Y, Ahnqvist O, Almqvist C, et al. Total MRI load of cerebral small vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 2014;71:855–862.
11. Gregg NM, Kim AE, Gurol ME, et al. Incidental cerebral microbleeds and cerebral blood flow in elderly individuals. JAMA Neurol 2015;72:1021–1028.
12. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016;36:172–186.
13. Welmer AK, Rizzuto D, Qiu C, Caracciolo B, Laukka EJ. Walking speed, processing speed, and dementia: a population-based longitudinal study. J Gerontol A Biol Sci Med Sci 2014;69:1503–1510.
14. Zhang Y, Qiu C, Lindberg O, et al. Acceleration of hippocampal atrophy in a nondemented elderly population: the SNAC-K study. Int Psychogeriatr 2010;22:14–25.
15. Wang R, Fratiglioni L, Kalpouzos G, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: a population-based study. Alzheimers Dement 2017;13:247–256.
16. Köhnicke Y, Laukka EJ, Brehmer Y, et al. Three-year changes in leisure activities are associated with concurrent changes in white matter microstructure and perceptual speed in individuals aged 80 years and older. Neurobiol Aging 2016;41:173–186.
17. Gerritsen L, Kalpouzos G, Westman E, et al. The influence of negative life events on hippocampal and amygdala volumes in old age: a life-course perspective. Psychol Med 2015;45:1219–1228.
18. Laveskog A, Wang R, Bronge L, Wahlund LO, Qiu C. Perivascular spaces in old age: assessment, distribution, and correlation with white matter hyperintensities. AJNR Am J Neuroradiol 2018;39:70–76.
19. Young VG, Halliday GM, Krid JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008;71:804–811.
20. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72–80.
21. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Winblad B. Clinical diagnosis of Alzheimer's disease and other dementias in a population survey. Agreement and causes of disagreement in applying Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, Criteria. Arch Neurol 1992;49:927–932.
22. Wang R, Fratiglioni L, Laukka EJ, et al. Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline. Neurology 2015;84:1128–1135.
23. Potter GM, Doubal FN, Jackson CA, et al. Enlarged perivascular spaces and cerebral small vessel disease. Int J Stroke 2015;10:376–381.
24. Apostolova LG, Zarow C, Biado K, et al. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement 2015;11:139–150.
25. Dong C, Nabizadeh N, Caunca M, et al. Cognitive correlates of white matter lesion load and brain atrophy: the Northern Manhattan Study. Neurology 2015;85:441–449.
26. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementia: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2013;10:642–653.
27. Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiological relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement (Amst) 2017;7:69–87.
28. Mattsson N, Tossu D, Insel PS, et al. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 2014;137(pt 5):1550–1561.
29. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer’s disease: lessons from pathology. BMC Med 2014;12:206.
30. Qiu C, Sigurdsson S, Zhang Q, et al. Diabetes, markers of brain pathology and cognitive function: the age, gene/environment susceptibility-Reykjavik Study. Ann Neurol 2014;75:138–146.
31. Kawar CH, Kim RC, Sonnen JA, et al. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ Study. Neurology 2015;85:535–542.
32. White LR, Edland SD, Hemmy LS, et al. Neuropathologic comorbidity and cognitive impairment in the nun and honolulu-Asia aging studies. Neurology 2016;86:1000–1008.
33. Nicoll JA, Sarva GM, Stewart J, et al. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales. Neuropathol Appl Neurobiol 2011;37:285–294.
34. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol 2015;72:511–519.
35. Boyle PA, Yang J, Yu L, et al. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain 2015;140:804–812.
36. Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol 2006;60:677–687.
37. Ye BS, Seo SW, Kim JH, et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology 2015;85:1687–1693.
38. Arba F, Quino T, Hankey GJ, Ali M, Lees KR, Inzitari D. Cerebral small vessel disease, medial temporal lobe atrophy and cognitive status in patients with ischaemic stroke and transient ischaemic attack. Eur J Neurol 2017;24:276–282.
39. Racine AM, Kosciuk RL, Berman SE, et al. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain 2016;139:2261–2274.